Global distribution partnership established for Strontium89
Q Biomed entered into a Named Patient Programme distribution agreement for Strontium89, a non-opioid metastatic bone cancer pain drug.
List view / Grid view
Q Biomed entered into a Named Patient Programme distribution agreement for Strontium89, a non-opioid metastatic bone cancer pain drug.
Research has predicted that the global single-use bioprocessing market will exhibit a CAGR of 13.6 percent over the forecast period until 2025.
In this Guide to QA/QC Instrumentation, we consider the Sievers M9 series of TOC Analyzers from GE Analytical Instruments, and METTLER TOLEDO’s UV7 Spectrophotometer...
In this Single Use In-Depth Focus: Disposables for continuous viral clearance for the production of monoclonal antibodies; Managing the quality of biologics manufactured by single use systems: A Japanese perspective; Single Use Q&A...
3 March 2016 | By Victoria White
AMRA Profiler is a cloud-based body composition measurement service, which uses images from a rapid, 6-minute MRI scan to deliver accurate, precise fat and muscle measurements...
8 February 2016 | By EBD Group
The tenth annual BIO-Europe Spring® springtime international life science partnering conference will be held in Stockholm, Sweden, April 4–6, 2016...
GE Healthcare’s most sensitive SPR-based sensor enables accurate interaction analysis of LMW fragments binding to difficult targets.
Our Application Notes & Whitepapers supplement covers a wide variety of applications, from NMR, biosensors, Raman spectroscopy and QC to hot-stage microscopy...
3 November 2015 | By London Business School
The Future of Healthcare - striking a balance between patients, value and innovation. Monday 7 December 2015...
14 October 2015 | By GE Healthcare
In this webinar, we discuss SPR fragment screening of wild type GPCRs enabled by sensitive biosensors and optimised membrane protein assays...
The precision of data from surface plasmon resonance (SPR)-based analyses, and the confidence with which results can be interpreted, is strongly coupled to the sensitivity of the SPR sensor. Biacore™ T200 system from GE Healthcare offers excellent sensitivity that enables detection of the lowest molecular-weight interactions and accurate measurements at…
This free-to-view Screening In-Depth Focus is packed with articles that will give you a greater understanding of interesting topics such as the identification of compounds that protect against free radicals, advancements in sandwich immunoassay techniques and hit validation and optimisation...
11 September 2014 | By Advanced Accelerator Applications and GE Healthcare
Advanced Accelerator Applications strengthens its position in the Italian PET Radiopharmaceutical Market...
21 February 2013 | By Sheraz Gul, Head of Biology at European ScreeningPort, Hamburg, Germany
Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide that now host infrastructure such as compound libraries and automated screening centres[1-3]. An archetypal small molecule drug discovery project will aim to identify…
18 December 2012 | By Merck
Clinical study collaboration announced...